- Report
- March 2024
- 198 Pages
Global
From €3242EUR$3,374USD£2,772GBP
€3602EUR$3,749USD£3,080GBP
- Report
- September 2019
- 40 Pages
Saudi Arabia
From €2493EUR$2,595USD£2,132GBP
- Report
- September 2019
- 40 Pages
Russia
From €2493EUR$2,595USD£2,132GBP
- Report
- September 2019
- 40 Pages
India
From €2493EUR$2,595USD£2,132GBP
- Report
- January 2021
- 144 Pages
China, Global
From €3000EUR$3,345USD£2,655GBP
- Report
- September 2019
- 40 Pages
United States
From €2493EUR$2,595USD£2,132GBP
- Report
- September 2019
- 40 Pages
Ireland
From €2493EUR$2,595USD£2,132GBP
- Report
- September 2019
- 40 Pages
Germany
From €2493EUR$2,595USD£2,132GBP
- Report
- September 2019
- 40 Pages
France
From €2493EUR$2,595USD£2,132GBP
- Report
- September 2019
- 40 Pages
China
From €2493EUR$2,595USD£2,132GBP
- Report
- September 2019
- 40 Pages
Brazil
From €2493EUR$2,595USD£2,132GBP
- Report
- September 2019
- 80 Pages
Africa
From €3646EUR$3,795USD£3,117GBP
- Report
- April 2023
- 147 Pages
Global
From €5764EUR$5,999USD£4,928GBP
Acetazolamide is a medication used in the treatment of cardiovascular diseases. It is a carbonic anhydrase inhibitor, which works by decreasing the production of bicarbonate in the body, thus reducing the amount of fluid in the blood vessels. This helps to reduce the pressure in the vessels, which can help to reduce the risk of stroke, heart attack, and other cardiovascular events. Acetazolamide is also used to treat glaucoma, epilepsy, and altitude sickness.
Acetazolamide is available in both generic and brand-name forms. It is typically taken orally, but can also be administered intravenously. Common side effects include nausea, vomiting, and dizziness.
The acetazolamide market is highly competitive, with many companies offering generic and brand-name versions of the drug. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and GlaxoSmithKline. Show Less Read more